AU2023382389A1 - Ahr agonists - Google Patents

Ahr agonists Download PDF

Info

Publication number
AU2023382389A1
AU2023382389A1 AU2023382389A AU2023382389A AU2023382389A1 AU 2023382389 A1 AU2023382389 A1 AU 2023382389A1 AU 2023382389 A AU2023382389 A AU 2023382389A AU 2023382389 A AU2023382389 A AU 2023382389A AU 2023382389 A1 AU2023382389 A1 AU 2023382389A1
Authority
AU
Australia
Prior art keywords
compound
mixture
pharmaceutically acceptable
acceptable salt
stereoisomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023382389A
Other languages
English (en)
Inventor
Michael Bell
Joel Calvin
Cheryl CARSON
Lacie CHAUVIGNE-HINES
Christian Clarke
Frank DORSEY
Douglas Gernert
Steven Green
William Mcmillen
Antonio Navarro
John Rizzo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2023382389A1 publication Critical patent/AU2023382389A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2023382389A 2022-11-15 2023-11-03 Ahr agonists Pending AU2023382389A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263425442P 2022-11-15 2022-11-15
US63/425,442 2022-11-15
PCT/US2023/078633 WO2024107555A1 (en) 2022-11-15 2023-11-03 Ahr agonists

Publications (1)

Publication Number Publication Date
AU2023382389A1 true AU2023382389A1 (en) 2025-05-15

Family

ID=89121650

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023382389A Pending AU2023382389A1 (en) 2022-11-15 2023-11-03 Ahr agonists

Country Status (17)

Country Link
US (1) US20240199608A1 (https=)
EP (1) EP4619401A1 (https=)
JP (2) JP7577819B2 (https=)
KR (1) KR20250083557A (https=)
CN (1) CN120225518A (https=)
AR (1) AR131070A1 (https=)
AU (1) AU2023382389A1 (https=)
CL (1) CL2025001421A1 (https=)
CO (1) CO2025005456A2 (https=)
CR (1) CR20250175A (https=)
DO (1) DOP2025000111A (https=)
IL (1) IL320832A (https=)
JO (1) JOP20250109A1 (https=)
MX (1) MX2025005566A (https=)
PE (1) PE20251588A1 (https=)
TW (2) TW202523664A (https=)
WO (1) WO2024107555A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240124A1 (en) * 2024-05-14 2025-11-20 Eli Lilly And Company Processes for preparing enantiomeric compounds and related molecules
CN120904199B (zh) * 2025-09-30 2026-03-06 上海泽德曼医药科技有限公司 具有稠环结构的化合物及其在医药上的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2510528A1 (de) * 1975-03-11 1976-09-23 Hoechst Ag Benzimidazo-/1,2-a/-chinoline und verfahren zu ihrer herstellung
NL7709746A (nl) * 1976-09-09 1978-03-13 Hoechst Ag Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen.
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
CN1149214C (zh) 1998-12-04 2004-05-12 东丽株式会社 三唑并衍生物和含有它们作为有效组分的趋化因子抑制剂
ATE463482T1 (de) 2002-07-25 2010-04-15 Janssen Pharmaceutica Nv Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
AU2004220176A1 (en) * 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
JP2007506788A (ja) * 2003-09-26 2007-03-22 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｈｃｖ感染阻害剤とその使用法
PL1753427T3 (pl) * 2004-05-28 2008-09-30 Janssen Pharmaceutica Nv Zastosowanie podstawionych pochodnych chinoliny do leczenia chorób wywoływanych przez prątki lekooporne
WO2007074491A1 (en) 2005-12-28 2007-07-05 Universita Degli Studi Di Siena HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS
WO2008014307A2 (en) 2006-07-26 2008-01-31 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
WO2018171602A1 (zh) 2017-03-21 2018-09-27 正大天晴药业集团股份有限公司 用于ido和tdo双重抑制剂的脲类化合物
US12312337B2 (en) * 2019-05-10 2025-05-27 Antidote Ip Holdings, Llc Compounds and methods for treating cancer
AR126963A1 (es) * 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr

Also Published As

Publication number Publication date
PE20251588A1 (es) 2025-06-16
KR20250083557A (ko) 2025-06-10
TW202523664A (zh) 2025-06-16
AR131070A1 (es) 2025-02-12
IL320832A (en) 2025-07-01
US20240199608A1 (en) 2024-06-20
JP2025032072A (ja) 2025-03-11
TW202434583A (zh) 2024-09-01
JOP20250109A1 (ar) 2025-05-13
WO2024107555A1 (en) 2024-05-23
CL2025001421A1 (es) 2025-08-18
DOP2025000111A (es) 2025-06-15
EP4619401A1 (en) 2025-09-24
JP7577819B2 (ja) 2024-11-05
CN120225518A (zh) 2025-06-27
JP2024072283A (ja) 2024-05-27
CO2025005456A2 (es) 2025-05-19
CR20250175A (es) 2025-05-27
TWI870104B (zh) 2025-01-11
MX2025005566A (es) 2025-06-02

Similar Documents

Publication Publication Date Title
CA3210332A1 (en) Tricyclic-amido-bicyclic prmt5 inhibitors
CN114539223A (zh) 一种含芳基并氮杂七元环类化合物及其制备方法与应用
CN112312904A (zh) 螺环化合物
KR102011770B1 (ko) 치환된 피리도피리미딘 화합물 및 flt3 억제제로서의 이의 용도
JP2019520396A (ja) Ｒｏｃｋ阻害剤としてのスピロ縮合環尿素
JP2021510151A (ja) アルツハイマー病等のタウ凝集体に関連する障害の治療、緩和、または予防のための１，３，４，５−テトラヒドロ−２ｈ−ピリド（４，３−ｂ）インドール誘導体
CA2402549A1 (en) Substituted beta-carbolines
US6194428B1 (en) Use of 5-substituted pyridine and hexahydroquinoline-3 carboxylic acid derivatives for treating diseases of the central nervous system
WO2024107555A1 (en) Ahr agonists
AU2002360618A1 (en) Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
WO2023039278A1 (en) Ahr agonists
TW202334167A (zh) 作為ｅｒｂｂ２抑制劑之稠合四環喹唑啉衍生物
KR20180049056A (ko) 삼환식 축합피리딘-2－온 유도체 및 이들의 brd4 저해제로서의 용도
KR20250080854A (ko) Pi3k 억제제로서의 이소퀴놀론
FI95795C (fi) Menetelmä terapeuttisesti käyttökelpoisten aminohappoantagonistien valmistamiseksi
AU2013276165B2 (en) Tricyclic compounds as KAT II inhibitors
JP5072595B2 (ja) マルチキナーゼ阻害剤
CN117769556A (zh) 嘧啶并环类衍生物及其制备方法和用途
CA2694994C (fr) Derives de n-heteroaryl-carboxamides tricycliques, leur preparation et leur application en therapeutique
JP5898233B2 (ja) 置換された水素化チエノ−ピロロ［３，２−ｃ］ピリジン、リガンド、医薬組成物及び上記を使用するための方法
KR20250095720A (ko) Ahr 효능제
CN118480047A (zh) 加兰他敏衍生物及其用途
AU2022341311A1 (en) Ahr agonists
US20040024009A1 (en) Dihydropyrazolo[3,4-d]thieno-[2,3-B]pyridinone inhibitors of B7-1
CN118215655A (zh) Ahr激动剂